• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Unimpressive From The Behemoth

Tech Letter

The most talked about topic at the forum of the elites in Davos, Switzerland was the souring economic environment globally.

That’s starting to look more real by the day as companies realize aggressive revenue estimates need to be flushed down the toilet.

As funny as it sounds, the January gangbuster rally could have been just a delayed Santa Claus Rally that got pushed back one month.

Now we are entering earnings season, and that means some companies won’t be able to spin numbers in the right way.

That bodes ill for many tech companies as, beneath the surface, the engine humming along that is the tech sector is starting to flash a few red lights.

Tech shares sold off sharply this morning which is quite unusual when the U.S. 10-year treasury barely moves.

Why did it open up poorly?

Microsoft offered us unimpressive guidance that was $2 billion less than the consensus.

Clearly, Microsoft is trying to lower the bar earlier than the other tech companies, boding ill for sector-wide guidance.

That’s highly unusual for the tech bellwether who has the habit of beating and raising forecasts almost systemically.

I can’t imagine tech firms in the ecommerce space like Amazon or Etsy offering better than expected guidance either for the annual year or the quarter’s ahead.

Microsoft was also one of those tech firms that took a machete to staff and sliced off a big chunk of them.

I would have liked to see Microsoft fire more than 10,000 workers and felt they could have easily handled a 50,000 reduction.

The $1.2 billion charge resulting from these layoffs is just a drop in the bucket for MSFT.

CEO Satya Nadella used the words "caution" at least six times on the one-hour  call on Tuesday.

Nadella also let investors know that Microsoft Azure, the cloud product, is slowing down to 31% and although still healthy, growth products aren’t growth products anymore when they dip into the 20% range.

The tech business model and the sector as a whole is getting a little stale.

They aren’t the shining stars of the equity market anymore as costs skyrockets and revenue decelerate. That designation is now reserved for energy and precious metals.

Don’t wait for tech to pull a rabbit out of the hat in the short run.  

The bad news is that it doesn’t seem that revenue weakness will only be confined to Microsoft.

A large swath of the tech sector could be painted red when it’s all said and done, which is why equity holders are betting on US Central Bank head Jerome Powell saving the day.

The silver liner on offer from Nadella was telling us how MSFT is betting the ranch on artificial intelligence particularly ChatGPT.

Artificial Intelligence inching closer to material revenue contribution is highly positive, but in the here and now, it’s hard to see where the incremental great idea comes from.

Nadella also told us that enterprise software isn’t doing as great because companies are being thriftier in what software they use.

Firms are cutting software and reducing their software footprint where they can get away with it.

Sales of Windows Licenses dropped 39% year over year highlighting the issue of companies attempting to universally cut costs.

When the overall economic mindset originates from a thrifty-based beginning, it doesn’t favor technology stocks.

Tech usually basks in the glory of the excesses, which is why they overshoot to the upside.

Hence, Chairman Powell is now priced in to singlehandedly rescue tech shares as many investors wait for his pivot back to zero interest rates yet again just like the 2008 Great Financial Crisis on repeat.

 

tech sector

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 15:02:192023-02-01 22:34:37Unimpressive From The Behemoth
Mad Hedge Fund Trader

Quote of the Day - January 25, 2023

Tech Letter

"I predict future happiness for Americans if they can prevent the government from wasting the labors of the people under the pretense of taking care of them." – Said 3rd U.S. President Thomas Jefferson

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2023/01/thomas-jefferson.png 646 436 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 15:00:152023-01-25 16:27:08Quote of the Day - January 25, 2023
Mad Hedge Fund Trader

Trade Alert - (META) January 25, 2023 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 10:49:202023-01-25 10:49:20Trade Alert - (META) January 25, 2023 - BUY
Mad Hedge Fund Trader

January 25, 2023

Diary, Newsletter, Summary

Global Market Comments
January 25, 2023
Fiat Lux

Featured Trade:

(TESTIMONIAL),
(THE BULL CASE FOR BANKS),
(JPM), (BAC), (C), (WFC), (GS), (MS)

 

CLICK HERE to download today's position sheet.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 09:06:042023-01-25 11:44:36January 25, 2023
Mad Hedge Fund Trader

Testimonial

Diary, Newsletter, Testimonials

Thanks, John for the Tesla trade.

I bought 40 contracts of the February $95-$100 vertical bull call spread at $3.75 and sold it this morning for $4.75 for a $4,000 gain.

NICE!

Penny in Florida

 

https://www.madhedgefundtrader.com/wp-content/uploads/2023/01/john-thomas-red-rock.jpg 324 432 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 09:04:352023-01-25 10:28:12Testimonial
Mad Hedge Fund Trader

January 25, 2023

Jacque's Post

 

Tuesday morning
January 24, 2023

Hello everyone or Bonjour,

I’m practicing my French, so I can keep up with Alex.

But I don’t yet know what the French is for anti-inflation bet.

It seems that’s how investors are approaching the market this year. Will it pan out this way?

Yes, markets are moving up slowly as they look forward to the end of the Federal Reserve’s interest rate hikes. In other words, they are looking through near-term economic weakness and toward the next Fed cutting cycle – even though the current hiking cycle is not yet over. With an expected 0.25% - 0.50% move on Feb 1, investors have grown more comfortable with owning stocks. Fed fund futures are even anticipating some mild rate cuts by the end of 2023, according to CME Group data.

But is it an error of judgment to assume that the Fed will not show such a hawkish tone on Feb 1?

Is the market underestimating the Fed’s desire to avoid a 1970’s style inflation resurgence?

The 1970s saw the central bank raise rates to control inflation, only to cut them on signs of economic weakness. The consequence of this was more increases in the early 1980s that sent the economy into a double-dip recession.

According to Data Trek Research, history shows that the Fed most often cuts policy rates during recessions … so, is the U.S. in recession now?

Food for thought.

The latest Time Magazine cover says it all:

A Picture of Red Lips with a zip across them. It seems the world is full of people who want to hold the floor and spotlight with their wordy content, but apparently, it is the people who say less, who will receive more.

Maybe, we’re just sick of all the noise!

 

 

Artificial Intelligence is motoring along at breakneck speed. Now we have ChatGPT. Will it work alongside us or instead of us?

Figureheads in education are scratching their heads.

I can see handwritten essays in class as the future to challenge the AI revolution.

Not sure how education will challenge the chip in the arm or the head scenario.

But wouldn’t that make us boring and stifle creativity?

See Mohamed El-Erian’s post below.

 

 

John closed out the February 95/100 TSLA vertical bull call spread today at $4.80 or best. That was a good decision as TSLA reports tomorrow and earnings results are uncertain. Clients who did this trade took home approximately $1,250 or 11.62% in 5 trading days. The $101 bottom in TSLA shares is looking quite solid.

Yesterday, John sent out a trade alert to buy the QQQ February 2023 $305-315 in the money vertical BEAR PUT spread at $9.00 or best.

Expiration Date: February 17

Stand aside if you don’t do options.

John is 71 years young on 26 Jan (Australia Day). Drop him a line. He’d love to hear from you.

Happy mid-week. Have a terrific day.

Cheers,
Jacque

“In order to write about life, first you must live it” - Ernest Hemingway

Subscription to Jacquie’s Post is on John’s site in his Store.

$170 USD/year.

Many thanks to those who are subscribers.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-25 01:00:282023-01-25 14:56:33January 25, 2023
Mad Hedge Fund Trader

January 24, 2023

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
January 24, 2023
Fiat Lux

Featured Trade:

(A MARKET-BEATING HEALTHCARE STOCK)
(LLY), (ABBV), (AMGN), (BMY), (GILD), (JNJ), (MRK), (PFE), (MRNA)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-24 14:02:442023-01-24 15:48:27January 24, 2023
Mad Hedge Fund Trader

A Market-Beating Healthcare Stock

Biotech Letter

The previous year was horrible for the stock market, with the S&P 500 dropping in value by roughly 19%, marking its first decline since 2018 and only the second time it sank since the 2008 financial crisis.

It was an even more horrid year for the biotechnology industry, with the flagship SPDR S&P Biotech ETF (XBI) sinking by 26% following its more than 20% decline in 2020—a catastrophic blow for such a promising index which delivered an impressive over 30% gains in 6 of the last 10 years.

Meanwhile, the stock prices in the large-cap pharmaceutical segment generally stayed buoyant. The “Big 8,” in particular—AbbVie (ABBV), Amgen (AMGN), Bristol Myers Squibb (BMY), Eli Lilly (LLY), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Merck & Co (MRK), and Pfizer (PFE)—reported an average share price gains of roughly 15%.

Among the names in this list, Eli Lilly has become one of the go-to “safe” stocks during these turbulent times.

In contrast to the broader market, the company has performed exceptionally well in the last 12 months, with its share prices climbing by 12% within the timeframe.

One of the critical reasons that propelled Eli Lilly’s performance was the regulatory approval it obtained for Mounjaro, a diabetes treatment, in May 2022. Although this pharma giant has been hailed as the leader in the diabetes care segment for decades, Mounjaro is a game changer.

This newly approved diabetes treatment could blow any competitor out of the water, with peak sales estimated to hit $25 billion.

Besides diabetes, Mounjaro is also under review as a potential obesity treatment, signifying label expansions for this drug.

If this pushes through, then Eli Lilly would become one of the first movers in the diabetes and obesity markets, with only Novo Nordisk (NVO) standing as a realistic challenger. Based on the market size and the lack of competitors, the profit margins for these segments could be likened to those recorded by Pfizer and Moderna (MRNA) for the COVID-19 vaccines.

There are also other promising candidates in Eli Lilly’s portfolio. One is Donanemab, which is a potential treatment for Alzheimer’s disease. According to the company's Phase 3 study, its candidate delivered better results than Biogen’s (BIIB) approved Alzheimer’s treatment, Aduhelm.

Eli Lilly recently sent its atopic dermatitis treatment candidate, Lebrikizumab, for regulatory review in both the US and Europe. This marks another potential blockbuster for the company, with many treatments queued for review and possible approval by the end of 2023.

As for the company’s current portfolio, most of its products still report good results. For instance, sales of its cancer drug Verzenio rose by 84% year over year to record $617.7 million in the third quarter of 2022. Revenue for the diabetes treatment Trulicity climbed 16% year over year to reach $1.9 billion.

Another factor that makes Eli Lilly attractive is its dividend. Over the past five years, the company has doubled its payout. In 2022, the company disclosed a 15% hike to its dividend payouts. This marked the fifth consecutive year Eli Lilly implemented.

In December 2022, Eli Lilly shared its updated guidance for 2023. For 2022, the company projected that its top line would be between $28.5 billion and $29 billion. That represents a modest growth rate. Eli Lilly shareholders can anticipate better performance this year.

For 2023, the company estimates sales to climb to $30.8 billion. While that amount may appear underwhelming, it’s essential to keep in mind that this is a very conservative estimate. Eli Lilly is taking into account several concerns that may affect its growth, such as patent exclusivity losses and a decline in its COVID-19 sales.

Overall, Eli Lilly has proven itself to be a good and solid business that looks in excellent shape to continue delivering market-beating returns.

With a market capitalization of over $350 billion and several candidates in its pipeline, this company has a strong potential to be worth much more in the following years. Also, it’s critical to bear in mind that since 2020, Eli Lilly shares have skyrocketed by 176%, dwarfing the S&P 500’s 20%—a trend I expect to continue. I suggest you buy the dip.

 

eli lilly market

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-24 14:00:422023-02-01 00:56:04A Market-Beating Healthcare Stock
Mad Hedge Fund Trader

Trade Alert - (PINS) January 24, 2023 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-24 11:42:462023-01-24 11:42:46Trade Alert - (PINS) January 24, 2023 - BUY
Mad Hedge Fund Trader

Trade Alert - (TSLA) January 24, 2023 - TAKE PROFITS - SELL

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-24 10:16:242023-01-24 10:16:24Trade Alert - (TSLA) January 24, 2023 - TAKE PROFITS - SELL
Page 4 of 15«‹23456›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top